Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Radiotherapy in marginal zone lymphoma

Authors: Kristin Deinbeck, Hans Geinitz, Bernhard Haller, Khashayar Fakhrian

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Purpose

To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone lymphoma (MZL).

Materials and methods

Patients with stage I (n = 22) and stage II (n = 8) MZL, who were treated with RT were reviewed. The primary tumor localisation was in the orbita (n = 12), stomach (n = 8), head and neck other than the orbita (n = 8), breast (n = 1) and one case of marginal zone lymphoma of the skin (n = 1). The median radiotherapy dose was 40 Gy (5 to 45 Gy).

Results

The median follow-up time was 103 months. The 5-year overall survival and event-free survival rates were 85 ± 7% and 71 ± 9%, respectively. There was no infield recurrence. Recurrence occurred outside of the radiation field in six patients. The relapses were treated with salvage RT and had excellent local control (100%) at five years after salvage RT.

Conclusions

Localized extranodal MZL have an excellent prognosis following moderate-dose RT. RT is also an effective salvage therapy in cases of localized recurrence. Further clinical studies should evaluate the optimal dose for MZL.
Appendix
Available only for authorised users
Literature
1.
Isaacson P, Wright DH: Malignant lymphoma of mucosa-associated lymphoid tissue: A distinctive type of B-cell lymphoma. Cancer 1983, 52: 1410-1416. 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3CrossRefPubMed
2.
Isaacson P: The MALT lymphoma concept updated. Ann Oncol 1995, 6: 319-320.PubMed
3.
Yamashita H, Nakagawa K, Asari T: Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol 2008, 87: 412-417. 10.1016/j.radonc.2008.03.012CrossRefPubMed
4.
Heinzelmann F, Engelhard M, Ottinger H, et al.: Nodal follicular lymphoma: The role of radiotherapy for stages I and II. Strahlenther Onkol 2010, 186: 191-196. 10.1007/s00066-010-2090-9CrossRefPubMed
5.
Thieblemont C, Bastion Y, Berger F, et al.: Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997, 15: 1624-1630.PubMed
6.
Goda JS, Gospodarowicz M, Pintilie M, et al.: Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010, 116: 3815-3824. 10.1002/cncr.25226CrossRefPubMed
7.
Hitchcock S, Ng AK, Fisher DC, et al.: Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2002, 52: 1058-1066. 10.1016/S0360-3016(01)02714-6CrossRefPubMed
8.
Liao Z, Ha CS, McLaughlin P, Manning JT, et al.: Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. Int J Radiat Oncol Biol Phys 2000, 48: 399-403. 10.1016/S0360-3016(00)00628-3CrossRefPubMed
9.
Tsang RW, Gospodarowicz MK, Pintilie M, et al.: Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003, 21: 4157-4164. 10.1200/JCO.2003.06.085CrossRefPubMed
10.
Tsang RW, Gospodarowicz MK, Pintilie M, et al.: Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001, 50: 1258-1264. 10.1016/S0360-3016(01)01549-8CrossRefPubMed
11.
Tomita N, Kodaira T, Tachibana H, et al.: Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol 2009, 90: 231-235. 10.1016/j.radonc.2008.12.004CrossRefPubMed
12.
Isobe K, Kagami Y, Higuchi K, et al.: A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys 2007, 69: 1181-1186. 10.1016/j.ijrobp.2007.04.029CrossRefPubMed
13.
Wenzel C, Fiebiger W, Dieckmann K, et al.: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer 2003, 97: 2236-2241. 10.1002/cncr.11317CrossRefPubMed
14.
Zucca E, Conconi A, Pedrinis E, et al.: Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003, 101: 2489-2495. 10.1182/blood-2002-04-1279CrossRefPubMed
15.
Anacak Y, Miller RC, Constantinou N, et al.: Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2012, 82: 315-320. 10.1016/j.ijrobp.2010.09.046CrossRefPubMed
16.
Bolek TW, Moyses HM, Marcus RB Jr: Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999, 44: 31-36. 10.1016/S0360-3016(98)00535-5CrossRefPubMed
17.
Schechter NR, Portlock CS, Yahalom J: Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998, 16: 1916-1921.PubMed
18.
Camacho FI, Algara P, Mollejo M, et al.: Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003, 27: 762-771. 10.1097/00000478-200306000-00006CrossRefPubMed
19.
Berger F, Felman P, Thieblemont C, et al.: Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000, 95: 1950-1956.PubMed
20.
Haidenberger A, Fromm-Haidenberger S, de Vries A: Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (rituximab®) for patients with Non-Hodkin’s lymphoma results of a prospective phase I/II study. Strahlenther Onkol 2011, 187: 300-305. 10.1007/s00066-011-2169-yCrossRefPubMed
21.
Schechter NR, Yahalom J: Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000, 46: 1093-1103. 10.1016/S0360-3016(99)00522-2CrossRefPubMed
22.
Fung CY, Tarbell NJ, Lucarelli MJ: Ocular adnexal lymphoma: clinical behavior of distinct world health organization classification subtypes. Int J Radiat Oncol Biol Phys 2003, 57: 1382-1391. 10.1016/S0360-3016(03)00767-3CrossRefPubMed
23.
Zhou P, Ng AK, Silver B, et al.: Radiation therapy for orbital lymphoma. Int J Radiat Oncol Biol Phys 2005, 63: 866-871. 10.1016/j.ijrobp.2005.03.005CrossRefPubMed
24.
Bessell EM, Henk JM, Wright JE, Whitelocke RA: Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 1988, 13: 237-244. 10.1016/0167-8140(88)90218-6CrossRefPubMed
25.
Lowry L, Smith P, Qian W, et al.: Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011, 100: 86-92. 10.1016/j.radonc.2011.05.013CrossRefPubMed
26.
Fakhrian K, Klemm S, Keller U, et al.: Radiotherapy in stage I–III follicular non-Hodgkin lymphoma. Strahlenther Onkol 2012. Epub ahead of print
27.
Zucca E, Dreyling M: ESMO guidelines working group. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010,21(Suppl 5):175-176.CrossRef
Metadata
Title
Radiotherapy in marginal zone lymphoma
Authors
Kristin Deinbeck
Hans Geinitz
Bernhard Haller
Khashayar Fakhrian
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-2

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer

Research

SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience

Research

Short–term effects of neoadjuvant chemoradiation therapy on anorectal function in rectal cancer patients: a pilot study

Research

Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer

Research

Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial

Research

Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma